Primary hemostasis (PH), i.e., hemostatic platelet plug formation, and the subsequent coagulation were recorded and quantified from the same nonanticoagulated venous blood sample with the use of the Haemostatometer®. In addition, platelet thrombus formation induced by interaction of flowing native blood with a collagen fiber under low shear rates (450 s" 1 ) was simultaneously analyzed by this device. The effect of monoclonal antibodies (MoAbs) directed against von Willebrand's factor antigen (vWF: Ag), platelet glycoprotein lb (GPIb) and the GPIIb/IIIa complex, and fibrinogen were studied. PH was significantly inhibited by MoAbs against v\VF:Ag, GPIIb/IIIa, and fibrinogen but was unaffected by antibody against GPIb. Collagen-induced thrombosis was prevented by MoAbs against v\VF:Ag and GPIb, slightly inhibited by antifibrinogen, and unaffected by blockage of platelet membrane GPIIb/IIIa. The effect of a single 600-mg dose of aspirin was monitored, and abnormal PH was still detectable five days later. 15 Thus, the results of such aggregation measurements are subject to artifacts and their relevance to platelet function in vivo is questionable.
crucial role in primary hemostasis, relevant platelet function measurement poses the major problem.
Platelet aggregation, 2 the most extensively used ex vivo platelet function measurement, has serious drawbacks. Separation of platelets from other blood cells alters their size, density, and behavior. Whole blood aggregometry 5 has overcome this limitation but created others, and anticoagulation and dilution of the blood is still necessary. Trisodium citrate removes most of the calcium ions, resulting in a truly unphysiologic situation in which the response of platelets to agonists is altered." 19 The other anticoagulant, heparin, has a direct effect on platelet function. 15 Thus, the results of such aggregation measurements are subject to artifacts and their relevance to platelet function in vivo is questionable.
The standardized template bleeding time 12 is regarded to be the most important screening test of platelet function in patients with bleeding tendency, and it is commonly used at lengthy intervals, such as the yearly review, to check on the hemostatic status of the patient. Because of scar formation and inconvenience, this test is not suitable for frequent use in monitoring therapy.
An instrument, called the Haemostatometer®, has recently been developed that allows the quantitative measurement of primary hemostasis from nonanticoagulated (native) undiluted whole blood samples. 810 This instrument monitors the pattern of hemostatic plug formation that occurs in holes in polyethylene tubing through which the blood flows under standard conditions. The pattern and rate of coagulation, subsequent to primary hemostasis, is also measured. In addition, the technique allows the simultaneous quantitative measurement of adhesion and aggregation of platelets on a collagen surface exposed to flowing native blood. The studies reported here were designed first to investigate the relevance of the measurements to the physiologic processes, then to define the usefulness of the technique to detect platelet function abnormalities and monitor therapy.
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Methods
The Haemostatometer
Monoclonal Antibodies (MoAbs)
Murine MoAbs, specific for various human antigens known to have an important role in hemostasis, were used to investigate the relative contribution of these factors in mediating platelet adherence and aggregation in the Haemostatometer. An MoAb (RFF-VIII:R/2) that binds specifically to von Willebrand's factor antigen (v\VF:Ag) in plasma but has no reactivity with Factor VIII procoagulant antigen has been described in detail elsewhere. 7 MoAb (AN 5) is directed against a site on platelet GPIb that blocks ristocetin-induced binding of von Willebrand's factor to the platelet and ristocetin-induced platelet agglutination. MoAb (M 148) is directed against an epitope on the GPIIb/IIIa complex that inhibits the binding of fibrinogen to platelets and adenosine diphosphate (ADP)-, and thrombin-induced platelet aggregation.
Patients
The patients were not selected, and the only criterion for inclusion was their availability for the study and the possibility of obtaining blood samples in a location very close to the instrument.
Eleven patients with hemophilia A, 2 patients with hemophilia B, 3 patients with Factor XI deficiency, 11 patients with von Willebrand's disease, and 2 patients with storage pool deficiency were tested. The characteristic factor levels and the subtypes are shown in Tables 1-3 . Six patients were studied before and after treatment with DDAVP or factor concentrates.
The controls consisted of 64 healthy hospital and medical school personnel (31 male and 33 female), with a mean age of 33 (range, 19-75) years. None of them admitted to have taken drugs known to interfere with platelet function for at least one week before the measurement.
Blood Samples
After informed consent, whole blood was obtained from patients, sometimes before and after treatment, and from normal healthy persons. With a tourniquet in place, antecubital venipuncture was done with a 21-gauge "butterfly" set having a 30-cm tubing length. The first 2 mL was set aside for routine hematology measurements, and then 2 mL blood was drawn into each of two plastic syringes and the hemostasis measurement started immediately. When MoAbs were tested, blood was drawn into two syringes: one contained the MoAb (5-10 fiL), the other the same volume of saline. The two samples were tested simultaneously.
An earlier form of the instrument has been described in detail. 8 ' 0 A simplified diagram of the main parts of the instrument is shown in Figure 1 .
The syringe with the native blood sample was inserted into the heated holder and the luer attached to a fitting accomodating two polyethylene tubings. A constant volume of paraffin oil was infused into the blood through the shorter tubing. The lighter oil bubbles up in the blood, preventing sedimentation of red blood cells and, by displacement, drives the blood through the longer tubing. The latter was threaded through the punching device and ended up in a perspex reservoir filled with paraffin oil. In the reservoir, the inflowing blood settles down and displaces the oil through a needle valve, set to allow 60 mmHg pressure to be built up in the system at an inflow rate of blood of 0.1 mL/minute. The perfusion pressure was recorded by a transducer through a sideport in the reservoir.
The mechanical punching device holds and guides a fine needle (0.15 mm diameter) that punches through in the tubing, making two holes. The Figure 1 inset shows the arrangement with the two channel apparatus. Two syringes with identical blood samples were used with two reservoirs side by side, but the punching was done by one needle.
Hemostasis and Clotting Measurement
The syringe with the blood sample was inserted into the holder, connected to the fitting, housing the polyethylene tubing, and the perfusion of blood was started by perfusing oil into the blood. After approximately 1 minute, a steady pressure was reached at 60 mmHg, at which point holes were made in the tubings with the punching device. This caused an immediate decrease in pressure, concomitant with the outflow of blood. The pattern of the pressure recovery shows how the hemostatic plugs build up in the holes. Because of a delay in detecting rapid pressure changes with the instrument, it was the 90% return of the pressure to the baseline level (and not the complete, i.e., 100%) that coincided with the stoppage of the "bleeding." The pressure thereafter remained steady at the 60 mmHg level until clotting occurred, which showed itself in the decline of the pressure. When clotting was complete, i.e., when the inflow of blood into the reservoir had stopped, the pressure rapidly decreased to zero. The time for the pressure to decrease to below 30 mmHg was defined as the clotting time and was calculated from the time the blood sample was drawn from the subject.
Platelet-Collagen Interaction Measurement
The principle of the measurement has been described earlier. 9 A 30-mm long piece of collagen fiber viz. surgical catgut (0.165 mm diameter, mostly type I collagen, 5/0 from Ethicon Ltd., Scotland) was placed and secured into the 0.5-mm-diameter lumen of the polyethylene tubing through which the native blood was perfused at a rate of 0.1 mL/minute. The corresponding wall shear rate, approximately 450 s -1 , was well within the physiologic range in small arteries. The rate and extent of the decline of the starting 60 mmHg pressure reflected the adhesion and aggregation of platelets on the collagen surface and the growth of thrombus, which finally became occlusive. This procedure needed no holes punched, the measurement being carried out simultaneously with the hemostasis/ clotting test in the second channel of the instrument, except that the polyethylene tubing bypassed the punching device.
Analysis of the Recordings
The pressure changes were monitored by a computer (BBC Master 128®), and the recordings were analyzed by a program. The time of punching was assigned as zero, and the original perfusion pressure before the punch was taken to be 100% and the minimum pressure after the punch to be 0%. After the punch, the formation of hemostatic plugs in the holes resulted in the recovery of the pressure from the minimum (0%) to the original level (100%). Two points were taken arbitrarily to characterize the pattern of the pressure changes, i.e., the hemostatic reaction. The time lapse required for pressure to reascend to 30% (30%s) characterized the initial phase of the reaction, determined by the rate of platelet aggregation immediately after the punch. The recovery time to the 90% pressure level (90%s) was essentially the in vitro bleeding time. This 90%s was influenced not only by the rate of platelet plug formation, but also by the stability of the thrombi formed. If the hemostatic plugs were not sufficiently firm to resist the increasing pressure, they were expelled; rebleeding occurred and the time for complete arrest of bleeding was prolonged. The areas of the respective parts of the pressure recordings were the 30%v and 90%v. These data show the volume (v) of "bleeding," i.e., the initial phase and the total volume, respectively. Analysis of these parameters is demonstrated in Figure 2A .
Recordings of thrombus formation on collagen fibers were analyzed as shown in Figure 2B . The rate and extent of the decline of perfusion pressure were calculated. Perfusion pressure decreased from the steady initial level either because of thrombus formation on the collagen fiber, which impeded the flow, or clotting. To ensure that clotting did not interfere with the measurement, an arbitrary endpoint of 7 minutes from the start of the perfusion of blood was chosen for analysis of the recordings. At this time (according to our experience in > 100 people), blood coagulation had not yet started and therefore did not interfere with the measurement. As a reliable index of the rate and extent of the reaction, the area of pressure decline until the seventh minute was calculated, as demonstrated in Figure IB .
Statistical Analysis
The level of significance of the differences between the two arithmetic means was calculated with Student's ttest.
Results
To test the reproducibility of the technique, blood samples were drawn and measured from the same volunteer daily for seven days. The 30% s/v; 90% s/v; clotting time and collagen 100% v values (mean ± SD) of the seven measurements were as follows: 58 ± 4; 565 ± 18; 127 ± 6; 2,987 ± 83; 823 ± 42; 11,267 ± 875, respectively. These data verify the good reproducibility of the technique.
Hemostasis and platelet collagen interaction measurements in the presence of different MoAbs directed against plasma or platelet membrane proteins are shown in Figures 3 and 4 . MoAbs against plasma von Willebrand's factor, which prevented ristocetin-induced platelet agglutination but had no effect on collagen-induced aggregation of platelets in citrated plasma, greatly prolonged hemostasis (Fig. 3A 2 ) and prevented thrombus formation on collagen (not shown). As with the blood drawn from a patient with von Willebrand's disease (Fig. 3A.1) , the antibody (Fig. 3A. 2) completely prevented the initial phase of the hemostatic reaction for several minutes, and the abrupt increase of the pressure thereafter probably resulted from clogging of the holes by clots, rather than by platelet aggregates. This assumption is based on findings using heparinized blood, where the pressure remained at the minimum until the blood supply ran out (not shown).
MoAbs against platelet GPIIb/IIIa greatly prolonged the in vitro hemostasis (Fig. 35.2 ) but had no effect whatsoever on collagen-induced thrombosis (not shown). On the other hand, MoAbs directed against platelet GPIb completely prevented collagen-induced thrombosis ( Fig.  4A.2) , without exerting any significant effect on hemostasis (not shown). MoAbs against fibrinogen inhibited hemostasis ( Fig. AB.2 ) but only slightly reduced the outcome of platelet-collagen interaction (not shown). The effect of a single 600-mg oral dose of aspirin is demonstrated in Figure 5 . Five days after the treatment, the in vitro hemostasis was still significantly prolonged in seven of eight volunteers.
The different parameters of in vitro hemostasis measured in patients were compared with the respective control values. These parameters were considered to be abnormal if they exceeded the 3 X SD of the respective control data. With the use of this arbitrary criterion, 7 of 13 classical hemophiliacs showed abnormal in vitro hemostasis, i.e., the characteristic data for the initial platelet plug formation (30% s/v) were over the 3 SD of the respective control values (Table 1) . When the in vitro bleeding time/volume data were compared, 9 of the 13 hemophiliacs were considered to be abnormal (>3 SD of the controls). The initial hemostatic reaction was abnormal in one patient of the three with Factor XI deficiency tested (Table 1) ; the in vitro bleeding time/volume were abnormal in two.
Hemostasis parameters of the 11 patients with von Willebrand's disease are shown in Table 2 . Hemostasis recordings were very similar to those obtained by adding MoAbs against von Willebrand's factor to normal blood (Fig. 3A.1) . Characteristic of the disease was the lack of any platelet reaction, i.e., plug formation immediately after the punch. This initial phase of the reaction is best characterized by the 30%v data, which were all above 3 X SD of the respective control values. In von Willebrand's disease, the interaction of platelets with collagen fiber was greatly reduced or absent. In both storage pool disease patients, hemostasis recordings were considered abnormal in comparison with the controls.
Haemostatometer measurements before and after factor replacement or DDAVP infusions are shown in Table 3 . All the in vitro hemostasis parameters tested improved significantly after therapy. Characteristic recordings of in vitro hemostasis in a patient with Factor XI deficiency before and after the factor-concentrate treatment are shown in Figure 6 .
Discussion
In the Haemostatometer, it is the shear stress and turbulence at the sites of the punched holes that initiate platelet aggregation and result in hemostatic plug formation. Previous studies showed that release of ADP from platelets and red blood cells and generation of thrombin are the major mediators of shear-induced platelet aggregation. 1324 Observations that hemostatic plug formation in the Haemostatometer is impaired by ADP antagonist 2-fluoroadenosine (unpublished) or by the thrombin antagonist hirudin 10 are consistent with this concept. In order to further clarify the relevance of data provided by the Haemostatometer to in vivo events, we conducted Recent studies indicate that von Willebrand's factor has an important role in supporting platelet-to-platelet aggregation. 17 Plasma or platelet von Willebrand's factor binds primarily to the GPIIb/IIIa complex when platelets are stimulated by ADP or thrombin. 20 
"
22 MoAbs against either von Willebrand's factor or GPIIb/IIIa strongly inhibited the Haemostatometer-induced hemostatic plug formation. Thus, our findings provide additional evidence that von Willebrand's factor is essential for shear stressinduced platelet-to-platelet interaction, i.e., for primary hemostasis or thrombosis.
It is also suggested that von Willebrand's factor mediates platelet-to-subendothelium attachment. The effect was seen only at high shear rates, much higher than those occurring in normal arteries. 23 Recent findings indicate that the subendothelium is, in itself, not thrombogenic and that the thrombogenicity depends upon exposure of collagenous structures at sites of vascular injury. 4 The basic difference between the present and the previous studies in this field is the use of fibrillar collagen (rather than amorphous collagen or denuded subendothelium) and, more importantly, nonanticoagulated blood. Our previous studies with the Haemostatometer have demonstrated a significant inhibition of platelet-collagen interaction by the presence of citrate, as anticoagulant. Our present findings, that platelet thrombus formation on collagen surface at low shear rates is prevented by MoAbs against von Willebrand's factor and its receptor on the platelet surface, the GPIb, provide the first evidence for the essential role of von Willebrand's factor in hemostasis and thrombosis under relevant physiologic conditions. During perfusion of native blood over the collagen fiber, contact activation of Factor XII and coagulation may occur and could contribute to the thrombus formation measured in the "collagen channel" of the Haemostatometer. The observation that MoAbs (against von Willebrand's factor and GPIb), which had very little effect on overall clotting time, prevented the collagen-induced thrombus formation supports the important role of platelets in the process. This is consistent with the findings that collagen fibrils or basement membrane alone cannot effectively activate Factor XII in normal plasma. 16 In addition, our present findings confirm that von Willebrand's factor is essential for the interaction of platelets with collagen.
The results of the experiments with the MoAbs demonstrated that the events in the Haemostatometer are relevant to important physiologic and pathologic processes.
It is known that aspirin increases the bleeding time in normal subjects by causing a platelet-release defect. Platelet release is an important constituent of hemostasis and the response to aspirin is a sensitive marker in the evaluation of platelet function. Aspirin-induced prolongation of the bleeding time has been used to discover patients with mild von Willebrand's disease abnormalities related to coagulopathy.
14 The Haemostatometer proved to be more sensitive in detecting the effect of aspirin than the skin bleeding-time measurement. Five days after a single dose of the drug, significantly prolonged hemostasis was detected by the Haemostatometer in almost all volunteers. On the other hand, the effect on the skin bleeding time was reported to diminish more rapidly, so that baseline values were reached four days after the administration of aspirin. 14 Our findings with aspirin and with the MoAbs predicted that the technique would detect abnormal hemostasis resulting from impaired platelet release or deficiencies in von Willebrand's factor, platelet glycoproteins, and hypofibrinogenemia. The expectations were confirmed when patients attending our clinic were studied with the Haemostatometer.
Eleven patients with von Willebrand's disease all showed prolonged primary hemostasis; in particular, the first part of the reaction (30% recovery time and volume) was inhibited. The most sensitive indication of the disease was the extreme inhibition or absence of collagen-induced thrombosis.
The prevailing opinion that primary hemostasis and bleeding time is normal in hemophilia has been challenged by some workers. u ' 6 Prolonged bleeding time and platelet functional abnormalities were observed in 20% of severe hemophiliacs. 3 We found that the time to achieve hemostasis, as well as the volume of the "bleeding," was significantly prolonged in an even higher (54%) proportion of patients with classical hemophilia A and B. Whether the inhibition of hemostatic plug formation was caused by delayed rate of thrombin generation and fibrin formation or by primary dysfunction of platelets, perhaps secondary to frequent transfusions of impure concentrates, has yet to be defined. Patients were reluctant to allow skin bleeding time measurement, and therefore we could not attempt to correlate our results with the skin bleeding times. In hemophiliacs with documented impaired in vitro hemostasis, as well as in patients with von Willebrand's disease, significant improvement of both the clotting time and primary hemostasis was demonstrated by the Haemostatometer after specific factor replacement or DDAVP therapy.
As a consequence of more accurate characterization of the functional domains of von Willebrand's factor and the receptor molecules on the platelet membrane, more specific and simpler therapeutic possibilities are emerging for patients with bleeding disorders. Because of the inconvenience caused and its inherent variabilities, the skin bleeding time technique is impractical for monitoring therapy. Measurement of platelet aggregation with different agonists is laborious, insensitive, and, in some respects, artifactual. This is evident from recent findings in patients with storage pool deficiency, where platelet aggregation measurements frequently failed to detect abnormalities in platelet function, despite the bleeding tendency and the demonstrated platelet-release defect. 18 Because no single clinically useful test exists for detecting platelet function disorder and monitoring therapy, such a test is urgently in demand. The lack of such a test causes difficulty in establishing the optimal dosages, time course, and assessment of the efficacy of treatments.
We now present our clinical experience with a technique that mimics the bleeding from an injured blood vessel, records not only the length of time but the volume and pattern of bleeding, and is acceptable to the patient because it is performed from a small volume of peripheral blood. Despite the substitution of the blood vessel with polyethylene tubing, the mechanism of the primary hemostasis in the Haemostatometer appears to be surprisingly similar to that occurring in vivo. Thus, we believe that, although the technique does not permit identification of specific coagulation or platelet disorders, it offers unique advantages in terms of clinical relevance and for monitoring therapy.
